Holen Sie sich die Stockscreener-App
14.45
4.15%
-0.6179
Schlusskurs vom Vortag:
$15.07
Offen:
$14.96
24-Stunden-Volumen:
1.39M
Relative Volume:
0.28
Marktkapitalisierung:
$1.02B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-6.2835
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
+15.38%
1M Leistung:
+35.89%
6M Leistung:
-69.02%
1J Leistung:
-72.62%
1-Tages-Spanne:
$14.10
$15.05
1-Wochen-Bereich:
$12.49
$15.55
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
14.45 | 1.07B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors - GlobeNewswire
SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations - ACCESS Newswire
Marshall Wace LLP Sells 111,706 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - ACCESS Newswire
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash - AOL.com
MLTX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
2025-12-07 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - The Malaysian Reserve
MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MLTX SECURITIES ALERT: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses of Important December 15 Securities Class Action Deadline - marketscreener.com
Are MoonLake (MLTX) Securities Lawsuits Quietly Reframing the Credibility of Its Drug Innovation Story? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
MLTX FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
MoonLake Immunotherapeutics Target of Unusually Large Options Trading (NASDAQ:MLTX) - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Why MoonLake Immunotherapeutics (MLTX) Is Up 9.2% After Lawsuits Challenging Sonelokimab Claims And What's Next - Yahoo Finance
MoonLake Immunotherapeutics (MLTX) Valuation After Class Action Lawsuits and Sonelokimab Trial Setbacks - simplywall.st
Levi & Korsinsky Helps Shareholders SueWallSt After MoonLake Immunotherapeutics Stock Drops - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class - GlobeNewswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.3%Still a Buy? - MarketBeat
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
FDA moving to one trial for approval could be positve for MoonLake, says Cantor - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
181,600 Shares in MoonLake Immunotherapeutics $MLTX Acquired by Decheng Capital LLC - MarketBeat
Levi & Korsinsky Invites Investors to SueWallSt After MoonLake Immunotherapeutics Stock Collapse - ACCESS Newswire
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
MOONLAKE STOCK ALERT: MoonLake Immunotherapeutics (MLTX) Investors Reminded to Contact BFA Law Prior to the December 15 Deadline in Securities Fraud Class Action - marketscreener.com
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
A better buy-in window may exist right now for MoonLake Immunotherapeutics (MLTX) - Setenews
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake’s SLK - GlobeNewswire
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - lelezard.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 15, 2025 to Discuss Your RightsMLTX - PR Newswire
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority - Finviz
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - MarketScreener
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
The Gross Law Firm Reminds MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
MoonLake Immunotherapeutics (NASDAQ: MLTX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - cnhinews.com
MLTX LEGAL ALERT: MoonLake Immunotherapeutics Hit with - GlobeNewswire
2025-11-30 | Investor Alert: Deadline Approaching to Join MoonLake Immunotherapeutics (MLTX) Class ActionContact Levi & Korsinsky | NDAQ:MLTX | Press Release - Stockhouse
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):